Brett E Fortune
Overview
Explore the profile of Brett E Fortune including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
79
Citations
548
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tsai C, Greenberg A, Flomenbaum D, Verzani Z, Garfunkel D, Brennan K, et al.
Hepatol Commun
. 2025 Feb;
9(3).
PMID: 40008904
No abstract available.
2.
Abboud Y, Rajan A, Rosenblatt R, Tow C, Jesudian A, Fortune B, et al.
J Clin Med
. 2024 Nov;
13(21).
PMID: 39518516
Acute kidney injury (AKI) is one of the common complications of liver cirrhosis. It occurs in nearly 20% of patients with cirrhosis who are hospitalized. Prior literature demonstrated that the...
3.
Kezer C, Berzigotti A, Fortune B, Simonetto D
Hepatology
. 2024 Oct;
PMID: 39378416
Cirrhosis is a prevalent condition affecting more than 100 million people globally and carrying significant morbidity and mortality related to the development of portal hypertension and hepatic decompensation. Current treatment...
4.
Vogel A, Roediger R, von Ahrens D, Fortune B, Schwartz J, Frager S, et al.
Life (Basel)
. 2024 Jun;
14(6).
PMID: 38929668
Poor metabolic health and obesity have significant impacts on the outcomes of patients suffering from chronic liver disease, particularly those with metabolic dysfunction-associated steatotic liver disease. Patients with such comorbidities...
5.
Charalel R, Mushlin A, Zheng X, Mao J, Carlos R, Brown Jr R, et al.
AJR Am J Roentgenol
. 2024 Jun;
223(2):e2431272.
PMID: 38899842
Differences in survival and morbidity among treatment options (ablation, surgical resection, and transplant) for early-stage hepatocellular carcinoma (HCC) have been well studied. Additional understanding of the costs of such care...
6.
Brahmania M, Rogal S, Serper M, Patel A, Goldberg D, Mathur A, et al.
Hepatol Commun
. 2024 May;
8(5).
PMID: 38696374
Racial, ethnic, and socioeconomic disparities exist in the prevalence and natural history of chronic liver disease, access to care, and clinical outcomes. Solutions to improve health equity range widely, from...
7.
Grover R, Fortune B, Tow C
Clin Liver Dis (Hoboken)
. 2024 Apr;
23(1):e0139.
PMID: 38567092
No abstract available.
8.
Serper M, Fortune B, Cardenas A, Brown Jr R
Liver Transpl
. 2024 Mar;
30(7):678.
PMID: 38551399
No abstract available.
9.
Wong R, Buckholz A, Hajifathalian K, Ng C, Sholle E, Ghosh G, et al.
J Clin Exp Hepatol
. 2023 Dec;
14(1):101255.
PMID: 38076370
Background: Patients with cirrhosis who have gastrointestinal bleeding have high short-term mortality, but the best modality for risk calculation remains in debate. Liver severity indices, such as Child-Turcotte-Pugh (CTP) and...
10.
Tow C, Chung E, Kaul B, Bhalla A, Fortune B
Clin Liver Dis
. 2023 Nov;
28(1):157-169.
PMID: 37945157
Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease characterized by progressive inflammation and fibrosis of the biliary tree leading to biliary strictures, cholangitis, and cirrhosis. Early in presentation,...